We have previously reported the therapeutic effect of blocking the IL-6/STAT3 pathway using IL-6R antibodies to reverse the imbalance in the Treg/Th17 ratio in NEC (35). The gene discussed is STAT3; the disease is necrotizing enterocolitis.